Silo Pharma (SILO) Non-Current Debt (2012 - 2021)
Silo Pharma (SILO) posted Non-Current Debt of $18900.0 for Q3 2021, little changed sequentially from $18900.0 in Q2 2021, and up 62.34% YoY from $11642.0 in Q3 2020.
Silo Pharma (SILO) Non-Current Debt (2012 - 2021) Analysis & Trends
Silo Pharma has reported Non-Current Debt for 4 years, with the latest figure at $18900.0 in Q3 2021.
- Quarterly Non-Current Debt rose 62.34% year-over-year to $18900.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $18900.0 (up 62.34% YoY) and the FY2020 annual result came in at $4246.0, changed N/A from the prior year.
- Non-Current Debt steadied at $18900.0 in Q3 2021 per SILO's latest filing, from $18900.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $18900.0 in Q2 2021 and troughed at $1063.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 18,900.00 |
| Jun 30, 2021 | 18,900.00 |
| Mar 31, 2021 | 1,063.00 |
| Dec 31, 2020 | 4,246.00 |
| Sep 30, 2020 | 11,642.00 |
| Jun 30, 2020 | 11,642.00 |
| Dec 31, 2013 | 15,000.00 |
| Dec 31, 2012 | 20,000.00 |
| Sep 30, 2012 | 15,000.00 |
| Jun 30, 2012 | 15,000.00 |
| Mar 31, 2012 | 15,000.00 |